NASDAQ · Health care

Processa Pharmaceuticals, Inc. (PCSA)

It posted a net loss of $13.4M. At June 30, 2026 it held $196.3K in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 14, 2026.

Price

$1.84

-0.54% on the day · September 25, 2026

52-week range $1.67 to $14.25

Market cap

$5.1M

What Processa Pharmaceuticals, Inc. does

Processa Pharmaceuticals, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker PCSA.

Revenue and profit by year

Revenue

Net income

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Fiscal year	Revenue	Operating income	Net income	Diluted EPS	Free cash flow
2025	n/a	-$14M	-$13.6M	-$10.36	n/a
2024	n/a	-$12.1M	-$11.9M	-$96.78	-$11.2M
2023	n/a	-$11.5M	-$11.1M	-$212.07	-$8.1M
2022	$0	-$27.5M	-$27.4M	-$851.51	n/a
2021	$0	-$12.1M	-$11.4M	-$18.76	n/a
2020	n/a	-$15.1M	-$14.4M	-$63.52	n/a

Full financial statements: income, balance sheet and cash flow

Next report expected around November 5, 2026.

Estimated from its filing rhythm: 52 weeks after its report of November 6, 2025. Not a date the company has announced. See the report calendar

Dividends

It paid out $42.9K in cash dividends.

Fiscal year	Per share	Paid out	Of profit
2015	n/a	$42.9K	n/a
2014	n/a	$45.6K	n/a

Per share as declared (or paid, where only that is reported), adjusted for stock splits the company itself restated. Yield is the latest fiscal year's dividend over the current price.

Latest SEC filings

What Processa Pharmaceuticals, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.

August 18, 2026
Passive stake (5% or more) SCHEDULE 13G
August 14, 2026
Quarterly report 10-Q · period to June 30, 2026Diluted EPS -$1.19 versus -$6.26.
August 4, 2026
Executive or director change 8-K
July 29, 2026
Acquisition or sale completed 8-K
June 18, 2026
Proxy statement DEF 14A
May 15, 2026
Passive stake changed SCHEDULE 13G/A
May 7, 2026
Quarterly report 10-Q · period to March 31, 2026Diluted EPS -$1.29 versus -$7.58.
April 30, 2026
Annual report (amended) 10-K/A · period to December 31, 2025Diluted EPS -$10.36 versus -$96.78.
April 30, 2026
Executive or director change 8-K
March 18, 2026
Annual report 10-K · period to December 31, 2025Diluted EPS -$10.36 versus -$96.78.

Recent insider filings (Forms 3, 4 and 144): 10, the latest on August 11, 2026. Insider transactions on SEC

Insider trades

What the people running Processa Pharmaceuticals, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.

No insider bought or sold shares on the open market in the last 90 days. The 1 reported changes were pay in shares, option exercises, shares withheld for tax or gifts.

Bought (open market)

last 90 days

Sold

last 90 days

Date	Insider	What	Shares	Price	Value	Filing
August 8, 2026	Ng George KChief Executive Officer, Director	Exercised options	1,600	-	-	Form 4

All insider filings on SEC.gov · Where insiders are buying across the market

Who owns PCSA

Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.

5% holders

Anyone who owns more than 5% of a class of shares must say so on Schedule 13D (if they may seek to influence the company) or 13G (a passive holder). The latest filing of each holder is shown: 13G filings of the last 2 years, 13D of the last 3.

Holder	Of class	Shares	Filed
HX Entertainment Ltd13D, may seek influence	13%	305,644	February 23, 2026
Mitchell P. Kopin13G, passive with 2 related filers	8.1%	200,000	February 13, 2026
CVI Investments, Inc.13G, passive with 1 related filers	7%	200,000	May 15, 2026
Soleus Capital Master Fund, L.P.13G, passive with 5 related filers	5.8%	160,943	August 18, 2026

Largest institutional holders

No Form 13F positions imported for this company yet.

Insiders

Reported holdings of insiders who filed a Form 4 in the last 12 months: the shares each one held after their latest reported transaction. This is not the total held by all insiders.

1 insiders reported holding 17,092 shares in total, about $31.4K at the last price.

Holder	Shares	As of
Ng George KChief Executive Officer, Director	17,092	August 8, 2026

Schedule 13D/13G filings on SEC.gov

All filings on SEC EDGAR

Questions about PCSA

What does Processa Pharmaceuticals, Inc. do?

Processa Pharmaceuticals, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker PCSA.

Is Processa Pharmaceuticals, Inc. profitable?

No. Over the twelve months to June 30, 2026 it reported a net loss of $13.4M.

When did Processa Pharmaceuticals, Inc. last report?

Its most recent periodic report is the quarterly report (10-Q) filed on August 14, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the passive stake (5% or more) from August 18, 2026.

Similar companies

Compare PCSA with

Compare PCSA with any company

Follow PCSA

Get an email when Processa Pharmaceuticals, Inc. files with the SEC: results, executive changes, material agreements and annual reports.

Follow PCSA: get an email when it files

Where the numbers come from

Financial figures are the values Processa Pharmaceuticals, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.